| Calhoun Medical Clinic, Llc | |
|
5135 Hwy 84w Laurel MS 39443 | |
| (601) 340-3544 | |
| (601) 651-2926 |
| Full Name | Calhoun Medical Clinic, Llc |
|---|---|
| Speciality | Family Medicine |
| Location | 5135 Hwy 84w, Laurel, Mississippi |
| Authorized Official Name and Position | Charlotte F Deloach (CFO) |
| Authorized Official Contact | 6014332998 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Calhoun Medical Clinic, Llc 5135 Hwy 84w Laurel MS 39443 Ph: (601) 340-3544 | Calhoun Medical Clinic, Llc 5135 Hwy 84w Laurel MS 39443 Ph: (601) 340-3544 |
| NPI Number | 1558713511 |
|---|---|
| Provider Enumeration Date | 07/01/2016 |
| Last Update Date | 07/01/2016 |
| Medicare PECOS PAC ID | 0941596084 |
|---|---|
| Medicare Enrollment ID | O20160915001795 |
News Archive
Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.
Conclusions about the effectiveness of blue light therapy for acne are limited. A new systematic review and meta-analysis of 14 randomized controlled trials of blue light therapy for acne shows methodological and reporting limitations-including small sample sizes, short intervention periods, and variation in reporting quality for acne outcomes.
Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data.
The longer you live the more likely you will develop a medical condition that requires surgery or a procedure. In fact, half of all people 65 and older will have at least one surgical procedure in their lifetime.
It seems that since the FDA approved the use of the abortion pill RU-486, (Mifeprex/ mifepristone) in September 2000, six women in the U.S. have died.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558713511 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 14545 (Mississippi) | Primary |
| Provider Name | Mark A Deloach |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1679681894 PECOS PAC ID: 4880620566 Enrollment ID: I20050722000525 |
News Archive
Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.
Conclusions about the effectiveness of blue light therapy for acne are limited. A new systematic review and meta-analysis of 14 randomized controlled trials of blue light therapy for acne shows methodological and reporting limitations-including small sample sizes, short intervention periods, and variation in reporting quality for acne outcomes.
Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data.
The longer you live the more likely you will develop a medical condition that requires surgery or a procedure. In fact, half of all people 65 and older will have at least one surgical procedure in their lifetime.
It seems that since the FDA approved the use of the abortion pill RU-486, (Mifeprex/ mifepristone) in September 2000, six women in the U.S. have died.
› Verified 1 days ago
| Provider Name | Stacey S Nix |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1154598357 PECOS PAC ID: 3173699154 Enrollment ID: I20080828000290 |
News Archive
Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.
Conclusions about the effectiveness of blue light therapy for acne are limited. A new systematic review and meta-analysis of 14 randomized controlled trials of blue light therapy for acne shows methodological and reporting limitations-including small sample sizes, short intervention periods, and variation in reporting quality for acne outcomes.
Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data.
The longer you live the more likely you will develop a medical condition that requires surgery or a procedure. In fact, half of all people 65 and older will have at least one surgical procedure in their lifetime.
It seems that since the FDA approved the use of the abortion pill RU-486, (Mifeprex/ mifepristone) in September 2000, six women in the U.S. have died.
› Verified 1 days ago
| Provider Name | Melissa A James |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356664825 PECOS PAC ID: 4688704992 Enrollment ID: I20100614000255 |
News Archive
Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.
Conclusions about the effectiveness of blue light therapy for acne are limited. A new systematic review and meta-analysis of 14 randomized controlled trials of blue light therapy for acne shows methodological and reporting limitations-including small sample sizes, short intervention periods, and variation in reporting quality for acne outcomes.
Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data.
The longer you live the more likely you will develop a medical condition that requires surgery or a procedure. In fact, half of all people 65 and older will have at least one surgical procedure in their lifetime.
It seems that since the FDA approved the use of the abortion pill RU-486, (Mifeprex/ mifepristone) in September 2000, six women in the U.S. have died.
› Verified 1 days ago
| Provider Name | Kenneth M Craven |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1750325528 PECOS PAC ID: 9537299680 Enrollment ID: I20100616000255 |
News Archive
Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.
Conclusions about the effectiveness of blue light therapy for acne are limited. A new systematic review and meta-analysis of 14 randomized controlled trials of blue light therapy for acne shows methodological and reporting limitations-including small sample sizes, short intervention periods, and variation in reporting quality for acne outcomes.
Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data.
The longer you live the more likely you will develop a medical condition that requires surgery or a procedure. In fact, half of all people 65 and older will have at least one surgical procedure in their lifetime.
It seems that since the FDA approved the use of the abortion pill RU-486, (Mifeprex/ mifepristone) in September 2000, six women in the U.S. have died.
› Verified 1 days ago
| Provider Name | Stephanie D Smith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1003055005 PECOS PAC ID: 8820113715 Enrollment ID: I20100915000975 |
News Archive
Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.
Conclusions about the effectiveness of blue light therapy for acne are limited. A new systematic review and meta-analysis of 14 randomized controlled trials of blue light therapy for acne shows methodological and reporting limitations-including small sample sizes, short intervention periods, and variation in reporting quality for acne outcomes.
Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data.
The longer you live the more likely you will develop a medical condition that requires surgery or a procedure. In fact, half of all people 65 and older will have at least one surgical procedure in their lifetime.
It seems that since the FDA approved the use of the abortion pill RU-486, (Mifeprex/ mifepristone) in September 2000, six women in the U.S. have died.
› Verified 1 days ago
| Provider Name | Kendall Thornton |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1134491806 PECOS PAC ID: 0840458592 Enrollment ID: I20120227000333 |
News Archive
Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.
Conclusions about the effectiveness of blue light therapy for acne are limited. A new systematic review and meta-analysis of 14 randomized controlled trials of blue light therapy for acne shows methodological and reporting limitations-including small sample sizes, short intervention periods, and variation in reporting quality for acne outcomes.
Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data.
The longer you live the more likely you will develop a medical condition that requires surgery or a procedure. In fact, half of all people 65 and older will have at least one surgical procedure in their lifetime.
It seems that since the FDA approved the use of the abortion pill RU-486, (Mifeprex/ mifepristone) in September 2000, six women in the U.S. have died.
› Verified 1 days ago
| Provider Name | Michael D Collins |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144532086 PECOS PAC ID: 2062674955 Enrollment ID: I20120511000011 |
News Archive
Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.
Conclusions about the effectiveness of blue light therapy for acne are limited. A new systematic review and meta-analysis of 14 randomized controlled trials of blue light therapy for acne shows methodological and reporting limitations-including small sample sizes, short intervention periods, and variation in reporting quality for acne outcomes.
Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data.
The longer you live the more likely you will develop a medical condition that requires surgery or a procedure. In fact, half of all people 65 and older will have at least one surgical procedure in their lifetime.
It seems that since the FDA approved the use of the abortion pill RU-486, (Mifeprex/ mifepristone) in September 2000, six women in the U.S. have died.
› Verified 1 days ago
| Provider Name | Courtney J Sims |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881227759 PECOS PAC ID: 8729419692 Enrollment ID: I20200508000405 |
News Archive
Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.
Conclusions about the effectiveness of blue light therapy for acne are limited. A new systematic review and meta-analysis of 14 randomized controlled trials of blue light therapy for acne shows methodological and reporting limitations-including small sample sizes, short intervention periods, and variation in reporting quality for acne outcomes.
Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data.
The longer you live the more likely you will develop a medical condition that requires surgery or a procedure. In fact, half of all people 65 and older will have at least one surgical procedure in their lifetime.
It seems that since the FDA approved the use of the abortion pill RU-486, (Mifeprex/ mifepristone) in September 2000, six women in the U.S. have died.
› Verified 1 days ago
| Provider Name | Eva D Pate |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093460099 PECOS PAC ID: 1355729708 Enrollment ID: I20220526000654 |
News Archive
Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.
Conclusions about the effectiveness of blue light therapy for acne are limited. A new systematic review and meta-analysis of 14 randomized controlled trials of blue light therapy for acne shows methodological and reporting limitations-including small sample sizes, short intervention periods, and variation in reporting quality for acne outcomes.
Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data.
The longer you live the more likely you will develop a medical condition that requires surgery or a procedure. In fact, half of all people 65 and older will have at least one surgical procedure in their lifetime.
It seems that since the FDA approved the use of the abortion pill RU-486, (Mifeprex/ mifepristone) in September 2000, six women in the U.S. have died.
› Verified 1 days ago
News Archive
Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its ImmunoSelect-R service designed to identify mutant neoantigens and support development of immuno-oncology cancer therapies.
Conclusions about the effectiveness of blue light therapy for acne are limited. A new systematic review and meta-analysis of 14 randomized controlled trials of blue light therapy for acne shows methodological and reporting limitations-including small sample sizes, short intervention periods, and variation in reporting quality for acne outcomes.
Corneal blindness is estimated to be the second most prevalent cause of blindness in many less developed countries. Globally, bilateral corneal blindness is estimated to afflict 4.9 million persons and accounts for 12% of 39 million blind, utilizing WHO 2010 global blindness data.
The longer you live the more likely you will develop a medical condition that requires surgery or a procedure. In fact, half of all people 65 and older will have at least one surgical procedure in their lifetime.
It seems that since the FDA approved the use of the abortion pill RU-486, (Mifeprex/ mifepristone) in September 2000, six women in the U.S. have died.
› Verified 1 days ago
Sc Wound Care & Hyperbaric Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1220 Jefferson St, Laurel, MS 39440 Phone: 601-426-4739 Fax: 601-426-4739 | |
Family Health Center Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 117 S 11th Ave, Laurel, MS 39440 Phone: 601-425-3033 Fax: 601-428-6561 | |
Family Health Center Hospital Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 117 S 11th Ave, Laurel, MS 39440 Phone: 601-425-3033 Fax: 601-422-0431 | |
Jefferson Medical Associates Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1203 Jefferson St, Laurel, MS 39440 Phone: 601-649-2863 Fax: 601-649-9479 | |
Immediate Care - Laurel Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2313 Highway 15 N, Laurel, MS 39440 Phone: 601-649-2775 Fax: 601-649-2686 | |
South Central Gastroenterology Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1203 Jefferson St, Laurel, MS 39440 Phone: 601-649-2863 Fax: 601-649-9479 | |
South Central Internal Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1203 Jefferson St, Laurel, MS 39440 Phone: 601-649-2863 Fax: 601-649-9479 |